Abstract: Prior art documents do not describe a method for modifying the surface of a calcium aluminate compound, much less describe a method for controlling the particle diameter of a calcium aluminate compound. The present invention provides a novel method for producing a calcium aluminate compound having a modified surface. The present invention provides: a method for producing a modified calcium aluminate compound characterized by irradiating a calcium aluminate compound dispersed in an organic dispersion medium with a femtosecond laser, thereby modifying the surface of the calcium aluminate compound; and a modified calcium aluminate compound characterized by being obtained by this method and having at least one of an OH group, a CO group, a CH group, and an NH group.

Abstract: An object of the present invention is to provide a therapeutic agent for hereditary spastic paraplegia (HSP) SPG4. Specifically, the present invention relates to a composition for preventing or treating a neurodegenerative disease such as hereditary spastic paraplegia SPG4, the composition comprising, as an active ingredient, a substance that inhibits a function of miR-33a.

Abstract: According to one embodiment, a structure evaluation system of the embodiments includes a plurality of sensors, a position locator, and an evaluator. The plurality of sensors detect elastic waves. The position locator locates elastic wave sources on the basis of a plurality of elastic waves detected by each of the plurality of sensors. The evaluator evaluates a deterioration state of a structure in accordance with a presence or absence of a sensor and an elastic wave source distribution which shows a position of the elastic wave sources obtained on the basis of a result of locating of the elastic wave sources.

Abstract: A method for manufacturing a GaN-based surface-emitting laser by an MOVPE includes: (a) growing a first cladding layer with a {0001} growth plane; (b) growing a guide layer on the first cladding layer; (c) forming holes which are two-dimensionally periodically arranged within the guide layer; (d) etching the guide layer by ICP-RIE using a chlorine-based gas and an argon; (e) supplying a gas containing a nitrogen to cause mass-transport, and then supplying the group-III gas for growth, whereby a first embedding layer closing openings of the holes is formed to form a photonic crystal layer; and (f) growing an active layer and a second cladding layer on the first embedding layer, The step (d) includes a step of referring to already-obtained data on a relationship of an attraction voltage and a ratio of gases in the ICP-RIE with a diameter distribution of air holes embedded, and applying the attraction voltage and the ratio to the ICP-RIE.

Abstract: A method for manufacturing a GaN-based surface-emitting laser by an MOVPE includes: (a) growing a first cladding layer with a {0001} growth plane; (b) growing a guide layer on the first cladding layer; (c) forming holes in a surface of the guide layer by etching, the holes being two-dimensionally periodically arranged within a plane parallel to the guide layer; (d) etching the guide layer by using an etchant having selectivity to the {0001} plane and a {10-10} plane of the guide layer; (e) supplying a gas containing a nitrogen source to cause mass transport without supplying a group-III material gas, and then supplying the group-III material gas for growth, whereby a first embedding layer closing openings of the holes is formed to form a photonic crystal layer; and (f) growing an active layer and a second cladding layer in this order on the first embedding layer.

Abstract: A proton conductor includes a complex of phosphoric acid and a coordination polymer in which a metal ion and a ligand are continuously connected by a coordinate bond. The phosphoric acid includes a first phosphoric acid that is coordinately bonded to the metal ion, and a second phosphoric acid that is not coordinately bonded to the metal ion.

Abstract: The invention provides a method of preparing a nucleic acid population suitable for RNA sequencing. The method involves amplifying a double-stranded DNA and a poly T sequence by using the DNA constituted of any additional nucleic acid sequence X, poly T sequence, mRNA sequence isolated from a biological sample, poly A sequence and any additional nucleic acid sequence Y in this order as a template, a first primer containing any additional nucleic acid sequence X having amine added to the 5?-terminal (and a poly T sequence), and a second primer containing any additional nucleic acid sequence Y (and a poly T sequence), followed by fractionalizing the DNA, phosphorylating the DNA, preparing cDNA by using the DNA as a template and a third primer, adding adenine (A) to the cDNA, linking a DNA, and amplifying the DNA by using the DNA as a template, a fourth primer, and a fifth primer.

Abstract: The present invention provides a prophylactic or therapeutic agent for Alzheimer's disease (AD) containing a combination of two or more compounds selected from the group consisting of compounds shown by compound Nos. 1 to 130. Since these compounds are existing drugs that have already been confirmed actually for safety and pharmacokinetics in human, they can be a means for a pre-emptive treatment of people at risk of AD and in a stage before developing mild cognitive impairment (MCI).

Abstract: A method for manufacturing a graft polymer, that ensures more stable progress of a living radical polymerization by using a monomer structural unit containing an iodine initiating group as an initiator, includes performing a living radical polymerization of a compound with a vinyl monomer by an organic catalyst to manufacture the graft polymer. The compound has a recurring unit represented by a formula (1) below in a main chain: where, R1: linking group (linear, branched, or cyclic alkylene group having 1 to 30 carbon atoms that may contain an ether bond, an amide bond, or an ester bond, an aromatic group), R2, R3, R4, R5, R6: an aromatic group, an aliphatic group, a hydrogen atom, an aliphatic group, and n=1 to 5.

Abstract: An object of the present invention is to provide a medium that comprises fewer protein components and enables the maintenance of pluripotent stem cells in an undifferentiated state. The culture medium for pluripotent stem cells comprises a GSK3? inhibitor (A) and a DYRK inhibitor (B).

Abstract: A computer calculates a change amount of a total number of electrons from an observation start time in the ionosphere between an observation station and a satellite based on observation data of a signal received from the satellite by the observation station on the ground. The computer estimates the change amount of the total number of electrons to be calculated next based on the time change of the change amount of the total number of electrons from the observation start time in the ionosphere and calculates a difference (estimation error) between the estimated change amount of the total number of electrons and the actually calculated change amount of the total number of electrons. The computer calculates a correlation value between the estimation error calculated for each observation station and the estimation error calculated for a predetermined number of the observation stations in the vicinity of each observation station.

Abstract: The present invention provides a method for screening for platelet production promoters, the method including a step for selecting a candidate substance that significantly increases expression of TUBB1 as a platelet production promoter.

Abstract: The inventors have found that the compounds of formula (I) protect cardiomyocytes. Accordingly, the disclosure provides a pharmaceutical composition for protecting a cardiomyocyte comprising a compound of formula (I) or an ester, oxide, pharmaceutically acceptable salt or solvate thereof. The pharmaceutical composition may be used for treating or preventing a disease associated with cardiomyocyte death, such as myocardial infarction, chronic heart failure, hypertensive heart failure, or dilated cardiomyopathy, especially for treating myocardial infarction.

Abstract: The present invention relates to a hydrophilic polyimide including at least one type of building blocks [A-B] and [A-C], and represented by the formula -[A-B]n-[A-C]m— (I), wherein: the n-bracketed building blocks and the m-bracketed building blocks are randomly distributed over the polyimide chain; repeat unit A results from a monomer comprising two carboxylic anhydride moieties, repeat unit B is hydrophilic and results from a first hydrophilic monomer comprising two primary amine moieties and at least one further hydrophilic moiety different from the primary amines, and repeat unit C is hydrophilic and results from a second hydrophilic monomer comprising two primary amine moieties and at least one further hydrophilic moiety different from the primary amines; wherein: n and m represent independently an integer from 0 to about 1000; wherein n+m is an integer from about 10 to about 1000.

Abstract: A non-transitory computer-readable storage medium storing a nonlinear optimization program of a continuous value optimization problem, the program relating to an optimization problem, is provided. The program causes an optimization apparatus to execute repeatedly and alternately procedure comprising: updating a variable of an evaluation function, causing an equality constraint to be gradually approached while searching for a condition at which the evaluation function approaches an extreme value; and updating the variable of the equality constraint, causing a condition at which the evaluation function to become close to the extreme value while keeping the equality constraint satisfied is gradually approached.

Abstract: Provided is a ligand capable of stably bonding together interfaces composed of different types of nanoparticles, different bulk interfaces, or an interface composed of nanoparticles and a bulk interface.

Abstract: The disclosure provides a compound of formula (I) for treating cerebral infarction, a pharmaceutical composition comprising the compound, a method of manufacturing a pharmaceutical composition for treating cerebral infarction comprising use of the compound, use of the compound for manufacturing a pharmaceutical composition for treating cerebral infarction, or a method for treating cerebral infarction comprising administering the compound or the pharmaceutical composition. The cerebral infarction includes, for example, lacunar infarction, atherothrombotic cerebral infarction, and cardiogenic embolism.

Abstract: According to the present invention, various diseases, such as viral diseases, cancer, and multiple sclerosis, can be prevented and improved by using an immunostimulatory factor production-promoting composition comprising genomic double-stranded RNA of a plant-derived endornavirus.

Abstract: Problem: To provide a production method for a perovskite layer using a tin-based perovskite compound having excellent flatness and a production method for a perovskite-type solar cell using the perovskite layer obtained by the above-described production method for the perovskite layer. Solution: A method for producing a perovskite layer that includes a step of applying a solution containing an Sn-based perovskite compound to a substrate, a step of applying a poor solvent to the substrate, and a step of performing an annealing process to the substrate, in this order, wherein the poor solvent is at 45° C. to 100° C.

Abstract: Provided is a pharmaceutical for preventing or treating an ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability. The inventors of the present invention have made investigations on a pharmaceutical for preventing or treating an ophthalmic disease associated with intraocular neovascularization and/or increased intraocular vascular permeability, and have confirmed that a selective S1P receptor agonist having agonist activity at an S1P1 receptor has an intraocular neovascularization-reducing action and an intraocular vascular permeability-reducing action, thus completing the present invention.